Hepion Pharmaceuticals Inc.

1.85+0.0200+1.09%Vol 1.26M1Y Perf 20.78%
Apr 9th, 2021 16:00 DELAYED
BID1.85 ASK1.86
Open1.83 Previous Close1.83
Pre-Market- After-Market-
 - -  - -%
Target Price
7.00 
Analyst Rating
Strong Buy 1.00
Potential %
278.38 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap141.02M 
Earnings Rating
Price Range Ratio 52W %
16.53 
Earnings Date
13th May 2021

Today's Price Range

1.811.88

52W Range

1.264.83

5 Year PE Ratio Range

-0.9000-0.3000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.04%
1 Month
-11.48%
3 Months
-16.67%
6 Months
-43.25%
1 Year
20.78%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
HEPA1.850.02001.09
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.51-0.69-35.29
Q02 2020-0.50-0.58-16.00
Q03 2019-0.64-0.5317.19
Q03 2018--0.03-
Q03 2017-0.14-0.0842.86
Q02 2017-0.14-0.1121.43
Q01 2017-0.14-0.137.14
Q04 2016-0.15-0.16-6.67
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date13th May 2021
Estimated EPS Next Report-
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.26M
Shares Outstanding76.23M
Trades Count3.50K
Dollar Volume20.91M
Avg. Volume5.94M
Avg. Weekly Volume1.73M
Avg. Monthly Volume4.68M
Avg. Quarterly Volume6.31M

Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) stock closed at 1.85 per share at the end of the most recent trading day (a 1.09% change compared to the prior day closing price) with a volume of 1.29M shares and market capitalization of 141.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Hepion Pharmaceuticals Inc. CEO is Robert T. Foster.

The one-year performance of Hepion Pharmaceuticals Inc. stock is 20.78%, while year-to-date (YTD) performance is -15.53%. HEPA stock has a five-year performance of %. Its 52-week range is between 1.26 and 4.83, which gives HEPA stock a 52-week price range ratio of 16.53%

Hepion Pharmaceuticals Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 12.57, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -80.38%, a ROC of -125.85% and a ROE of -129.22%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Hepion Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Hepion Pharmaceuticals Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Hepion Pharmaceuticals Inc. is Strong Buy (1), with a target price of $7, which is +278.38% compared to the current price. The earnings rating for Hepion Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Hepion Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Hepion Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.77, ATR14 : 0.24, CCI20 : -58.49, Chaikin Money Flow : -0.12, MACD : -0.11, Money Flow Index : 42.56, ROC : -9.42, RSI : 45.22, STOCH (14,3) : 49.35, STOCH RSI : 1.00, UO : 55.55, Williams %R : -50.65), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Hepion Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Moderate Buy
1.67

Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. The company's cyclophilin inhibitor, CRV431 targets multiple biochemical pathways involved in the progression of liver disease.

CEO: Robert T. Foster

Telephone: +1 732 902-4000

Address: 399 Thornall Street, Edison 08837, NJ, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

52%48%

Bearish Bullish

57%43%

Bearish Bullish

56%44%

News

Stocktwits